Table 3.

Adverse drug reactions and dropout rate.

Study	ADRs			Dropout rate (%)
	Events	Treatment (%)	Control (%)	Total (%)	Treatment (%)	Control (%)
RCTs
Lenze et al., 2021	Pneumonia	3 (3.8)	6 (8.3)	Fluvoxamine-treated participants, 18 of 80 stopped responding to the surveys prior to day 15 compared with 19 of 72 who were randomized to placebo	18 (22.5)	19 (26.4)
	Shortness of breath	2 (2.5)	4 (5.6)
	Headache or head pain	2 (2.5)	1 (1.4)
	Gastroenteritis, nausea, or vomiting	1 (1.3)	5 (6.9)
	Muscle aches	1 (1.3)	0
	Bacterial infection	1 (1.3)	0
	Vasovagal syncope	1 (1.3)	0
	Teeth chattering	1 (1.3)	0
	Dehydration	1 (1.3)	0
	Low oxygen saturation or hypoxia	0	6 (8.3)
	Chest pain or tightness	0	2 (2.8)
	Fever	0	2 (2.8)
	Acute respiratory failure	0	1 (1.4)
	Hypercapnia	0	1 (1.4)
	Flank pain	0	1 (1.4)
	Serious adverse eventsa	1 (1.3)	5 (6.9)
	Other adverse eventsb	11 (13.8)	6 (8.3)
Reis et al., 2021	No significant differences in the fluvoxamine and placebo groups			330 (22.0)	193 (26.0)	137 (18.0)
Prospective cohort study
Seftel et al., 2021	No serious ADRs occurred with fluvoxamine			NR
Calusic et al., 2021a, Calusic et al., 2021b	NR	NR	NR	NR
Retrospective study
Németh et al., 2021	NR	NR	NR	NA
Hoertel et al., 2021	NR	NR	NR	NA
Oskotsky et al., 2021	NR	NR	NR	NA

Abbreviations: ADRs = adverse drug reactions; NR = not reported; NA = not applicable; RCT = randomized controlled trial.

^aSerious adverse events = One patient in the placebo group had more than 1 serious adverse event. The total No. of serious adverse events was 1 in the fluvoxamine group and 6 in the placebo group.

^bOther adverse events = There were patients in the placebo group who had more than 1 other adverse event.